🏛️ Verified NIH Record • Updated 2026-04-23
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer (NCT04665947)
🟢 Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: University of California, Davis
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
Who can join: Review the eligibility criteria below.
Location: University of California Davis — Sacramento, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of California Davis — Sacramento, California
📞 Contact the Study Coordinator
Phone: (916) 734-5536
Email: jlsutcliffe@ucdavis.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Pancreatic Cancer
- Proglumide and Chemotherapy for Metastatic Pancreatic Cancer — Washington D.C., District of Columbia
- Saltikva for Metastatic Pancreatic Cancer — Montreal, Quebec
- Redefining FOLFIORINOX in Older Pancreatic Cancer Patients — Philadelphia, Pennsylvania
- Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy — New Hyde Park, New York
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. — Baltimore, Maryland
- Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer — Dallas, Texas
Explore by condition: All Metastatic Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.